Clinical diagnostic services
BRACAnalysis®
Testing for Hereditary Breast & Ovarian Cancer (HBOC) Syndrome
Proactive cancer management through early risk identification
What is BRACAnalysis®?
BRACAnalysis® assesses a woman's risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes.
Why choose the BRACAnalysis® test?
BRACAnalysis® genetic testing enables the clinician to:
- Advise the patient from the most accurate predisposition test available
- Receive results more rapidly than other services, which minimises stressful patient waiting time
- Take a proactive management approach with clearly identified at-risk patients
- Avoid unnecessary interventions in family members who have not inherited a known familial mutation
- Target increased surveillance and other interventions to individuals with a BRCA1 or BRCA2 mutation – maximising patient care while increasing clinical efficiency
- Counsel patients and family members on the underlying cause of cancer, in the case of a positive result
- Significantly improve patient outcomes
Who should be tested?
Individuals with a BRCA1 or BRCA2 mutation have a 50% (or 1 in 2) chance of passing that mutation on to each of their offspring.
Individuals with a personal and /or family history of any of the following may benefit from BRACAnalysis®.
- Early onset of breast cancer prior to age 50
Ovarian cancer at any age - Multiple breast and/or ovarian cancer diagnoses in an individual or family
- Women of Ashkenazi Jewish descent diagnosed with breast cancer prior to age 50 or ovarian cancer at any age, regardless of family history
- Male breast cancer
To see more information on this test please click here (PDF)
Myriad and BRACAnalysis are either trademarks or registered trademarks of Myriad Genetics, Inc in the United States and other jurisdictions
Product
sheet PDF
What is the test?
BRACAnalysis® is a genetic test that requires only a blood sample to determine whether a patient has a BRCA1 or BRCA2 gene mutation, indicating a predisposition to breast and ovarian cancer. This is the most accurate clinical test available to detect BRCA1 and BRCA2 gene mutations.
From receipt of the patient samples at Myriad’s testing laboratory, a report will be sent within 21 working days. If additional large rearrangement analysis is required, allow an additional 21 working days for this seperate report. If results are required urgently a rapid service is also available, for an additional fee, with gene sequence analysis results within 12 working days.
